Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2021 > Vol 2, №6 (2021) > Risks, urological complications and possible ways to overcome the COVID neuroinfection (clinical lecture)

Risks, urological complications and possible ways to overcome the COVID neuroinfection (clinical lecture)

Vladimir V. Borisov

For citation:


  • Abstract
  • About the Author
  • References

Abstract

In patients with coronavirus infection, the nervous system involvement is very diverse. It undeniably directly affects the function of genitourinary system and other body systems. This can be most prominently manifested in urination, the complex and complicated process of bladder emptying. These symptoms are well-known and can be identified from the very first minutes of doctor-patient communication under the condition of knowledge about the symptoms and willingness for focused identification. Conscious control of urination requires complex interactions between the autonomic (sympathetic and parasympathetic) and the somatic nervous system. Medical history is important for diagnosis. On the one hand, the information obtained is twice as subjective, being the physician’s subjective assessment of the patient’s subjective perceptions. However, one should not forget about the need for individual approach to diagnosis taking into account each patient’s characteristics. Drug therapy should be accomplished only through the joint effort of urologist and neurologist during both therapy and rehabilitation.

Key words: coronavirus, neuroinfection, mental disorders, multidisciplinary approach, lower urinary tract, anticholinergics.

About the Author

Vladimir V. Borisov 1

1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

References

1. Wu ZS, Zhang ZQ, Wu S. Focus on the Crosstalk Between COVID-19 and Urogenital Systems. J Urol 2020. Apr 3. DOI: 10.1097/JU.0000000000001068 
2. Peng L, Liu J, Xu W et al. SARS-CoV-2 Can Be Detected in Urine, Blood, Anal Swabs, and Oropharyngeal Swabs Specimens. J Med Virol 2020. Apr 24. DOI: 10.1002/jmv.25936 
3. Guan WJ, Ni ZY, Hu Yet al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med 2020; 382 (18): 1708–20. DOI: 10.1056/NEJMoa2002032
4. Sun J, Zhu A, Li H et al. Isolation of Infectious SARS-CoV-2 from Urine of a COVID-19 Patient. Emerg Microbes Infect 2020; 28: 1–8. DOI: 10.1080/22221751.2020.1760144 
5. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA 2020; 323 (18): 1843–4. DOI: 10.1001/ jama.2020.3786 
6. Vishnevskii E.L., Pushkar' D.Iu., Loran O.B. et al. Urofloumetriia. M.: Pechatnyi Gorod, 2004 (in Russian).
7. Andrew J, Nathan PW. Lesions of the anterior frontal lobes and disturbances of micturition and defecation. Brain 1964; 87: 233–62.
8. Griffiths, Derek J. Use of functional imaging to monitor central control of voiding in humans. Urinary Tract. Springer, Berlin, Heidelberg, 2011. P. 81-97 
9. Vishnevskii E.L., Pushkar' D.Iu., Loran O.B. et al. Urofloumetriia. Moscow: Pechatnyi Gorod, 2004 (in Russian).
10. Burkhard F.C. (Chair) et al. EAU Guidelines on Urinary Incontinence, 2016.
11. Napier & Gupta Darifenacin is selective for the human recombinant M3 receptor subtype. Neurourol Urodyn 2002; 21: A445.
12. Doroshyenko et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 2005; 44 (7): 701–20. 
13. Waterbeemd et al Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 1998; 6: 151–5.
14. Kessler TM et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One 2011; 6 (2): e16718. 
15. Staskin D, Kay G, Tannenbaum C et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010; 64 (9): 1294–300.
16. Abrams P et al. Incontinence: 5th International Consultation on Incontinence, Paris, February 2012. 5th Edition. ICUD-EAU, 2013.
17. Pietzko et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacology 1994; 47: 337–43.
18. Diefienbach K, Maurer A et al. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig 2003; 23 (6): 395–404.
19. Herberg KW, Fussgen I: Einfluss von Trospiumchlorid, Oxybutynin-HCl und Propiverin-HCl auf sicherheitsrelevante Leistungen. Geriatrie Forschung 1997; 7 (2): 77–83.
20. Rudy D. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU International 2006; 97: 540–46.

For citation:Borisov V.V. Risks, urological complications and possible ways to overcome the COVID neuroinfection (clinical lecture). Clinical review for general practice. 2021; 6: 35–41. DOI: 10.47407/kr2021.2.6.00078


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru